Free Trial

West Pharmaceutical Services (WST) Financials

West Pharmaceutical Services logo
$210.85 +5.26 (+2.56%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$210.91 +0.06 (+0.03%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for West Pharmaceutical Services

Annual Income Statements for West Pharmaceutical Services

This table shows West Pharmaceutical Services' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
493 593 586 662 346 242 207 151 144 96
Consolidated Net Income / (Loss)
493 593 586 662 346 242 207 151 144 96
Net Income / (Loss) Continuing Operations
493 593 586 662 346 242 207 151 144 96
Total Pre-Tax Income
586 698 680 749 401 292 241 222 190 116
Total Operating Income
570 676 734 752 407 297 240 226 195 129
Total Gross Profit
999 1,129 1,136 1,176 768 606 545 513 501 456
Total Revenue
2,893 2,950 2,887 2,832 2,147 1,840 1,717 1,599 1,509 1,400
Operating Revenue
2,893 2,950 2,887 2,832 2,147 1,840 1,717 1,599 1,509 1,400
Total Cost of Revenue
1,895 1,821 1,751 1,656 1,379 1,234 1,172 1,086 1,008 944
Operating Cost of Revenue
1,895 1,821 1,751 1,656 1,379 1,234 1,172 1,086 1,008 944
Total Operating Expenses
429 453 402 424 361 309 305 287 306 327
Selling, General & Admin Expense
339 353 317 363 302 273 263 246 240 233
Research & Development Expense
69 68 59 53 47 39 40 39 37 34
Other Operating Expenses / (Income)
21 31 27 7.90 12 -2.50 1.90 2.00 30 60
Total Other Income / (Expense), net
16 22 -54 -3.40 -5.60 -4.80 0.40 -3.40 -5.40 -13
Interest Expense
3.00 9.00 7.90 8.20 8.20 8.50 8.40 7.80 8.10 14
Interest & Investment Income
20 28 5.10 1.00 1.40 3.80 2.10 1.30 1.10 1.60
Other Income / (Expense), net
-1.00 3.00 -51 3.80 1.20 -0.10 6.70 3.10 1.60 -
Income Tax Expense
108 122 115 107 73 59 41 81 54 26
Other Gains / (Losses), net
15 18 21 20 17 8.90 7.60 9.20 8.20 5.80
Basic Earnings per Share
$6.75 $7.98 $7.87 $8.89 $4.68 $3.27 $2.80 $2.04 $1.96 $1.33
Weighted Average Basic Shares Outstanding
73M 74.30M 74.40M 74.40M 73.90M 74M 73.90M 73.90M 73.30M 72M
Diluted Earnings per Share
$6.69 $7.88 $7.73 $8.67 $4.57 $3.21 $2.74 $1.99 $1.91 $1.30
Weighted Average Diluted Shares Outstanding
73.70M 75.30M 75.80M 76.30M 75.80M 75.40M 75.40M 75.80M 75M 73.80M
Weighted Average Basic & Diluted Shares Outstanding
72.30M 73.30M 74.14M 74.28M 74.10M 147.67M 73.90M 73.90M 73.30M 71.90M
Cash Dividends to Common per Share
$0.82 $0.78 $0.74 $0.70 $0.66 $0.62 $0.58 $0.54 $0.50 $0.46

Quarterly Income Statements for West Pharmaceutical Services

This table shows West Pharmaceutical Services' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
90 130 136 111 115 137 161 155 140 103 121
Consolidated Net Income / (Loss)
90 130 136 111 115 137 161 155 140 103 121
Net Income / (Loss) Continuing Operations
90 130 136 111 115 137 161 155 140 103 121
Total Pre-Tax Income
111 165 165 129 127 168 187 185 158 129 136
Total Operating Income
107 160 161 126 123 161 177 183 155 130 186
Total Gross Profit
232 274 265 230 230 278 288 291 271 262 268
Total Revenue
698 749 747 702 695 732 747 754 717 709 687
Operating Revenue
698 749 747 702 695 732 747 754 717 709 687
Total Cost of Revenue
466 475 482 472 465 454 459 462 445 447 419
Operating Cost of Revenue
466 475 482 472 465 454 459 462 445 447 419
Total Operating Expenses
125 114 103 104 107 117 111 109 116 132 82
Selling, General & Admin Expense
88 85 84 83 87 90 89 88 86 86 66
Research & Development Expense
16 19 16 18 18 18 16 17 17 16 14
Other Operating Expenses / (Income)
21 10 4.40 3.30 3.10 8.90 5.60 4.00 13 31 1.90
Total Other Income / (Expense), net
3.50 5.30 3.20 2.50 4.60 7.30 9.70 2.40 2.60 -1.00 -50
Interest Expense
0.40 -0.80 0.70 1.50 1.60 1.20 2.90 2.70 2.20 1.70 2.20
Interest & Investment Income
4.10 4.80 4.60 4.00 6.20 9.40 8.80 5.00 4.80 2.90 1.50
Other Income / (Expense), net
-0.20 - -0.70 0.00 - - 3.80 0.10 - - -49
Income Tax Expense
24 37 32 22 16 35 29 35 24 29 20
Other Gains / (Losses), net
3.40 2.00 3.90 4.50 4.30 3.30 3.70 5.00 5.70 3.20 4.80
Basic Earnings per Share
$1.24 $1.79 $1.87 $1.52 $1.57 $1.85 $2.17 $2.08 $1.88 $1.38 $1.62
Weighted Average Basic Shares Outstanding
72.50M 73M 72.80M 73M 73.50M 74.30M 74.30M 74.30M 74.50M 74.40M 74.40M
Diluted Earnings per Share
$1.23 $1.78 $1.85 $1.51 $1.55 $1.83 $2.14 $2.06 $1.85 $1.37 $1.59
Weighted Average Diluted Shares Outstanding
73M 73.70M 73.40M 73.70M 74.30M 75.30M 75.30M 75.40M 75.70M 75.80M 75.70M
Weighted Average Basic & Diluted Shares Outstanding
71.85M 72.30M 72.42M 72.54M 72.84M 73.30M 73.99M 73.86M 74.24M 74.14M 74.03M
Cash Dividends to Common per Share
$0.21 - - $0.20 $0.20 - - $0.19 $0.19 - -

Annual Cash Flow Statements for West Pharmaceutical Services

This table details how cash moves in and out of West Pharmaceutical Services' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
-369 -40 132 147 176 102 102 33 -72 19
Net Cash From Operating Activities
653 777 724 584 473 367 289 263 219 212
Net Cash From Continuing Operating Activities
653 779 724 584 473 367 289 263 219 212
Net Income / (Loss) Continuing Operations
493 593 586 662 346 242 207 151 144 96
Consolidated Net Income / (Loss)
493 593 586 662 346 242 207 151 144 96
Depreciation Expense
152 134 117 117 105 100 102 94 88 86
Amortization Expense
3.60 3.60 3.70 5.40 4.40 3.40 2.70 2.40 2.60 3.80
Non-Cash Adjustments To Reconcile Net Income
5.90 69 63 41 33 21 5.30 16 22 47
Changes in Operating Assets and Liabilities, net
-0.60 -20 -46 -241 -16 0.90 -28 0.30 -37 -20
Net Cash From Investing Activities
-379 -369 -288 -253 -180 -228 -101 -134 -176 -130
Net Cash From Continuing Investing Activities
-379 -369 -288 -253 -180 -228 -101 -134 -176 -130
Purchase of Property, Plant & Equipment
-377 -362 -285 -253 -174 -126 -105 -131 -170 -132
Other Investing Activities, net
-1.70 -6.70 -3.60 2.50 -5.10 2.40 3.90 3.20 2.80 3.60
Net Cash From Financing Activities
-623 -460 -294 -168 -137 -37 -81 -109 -114 -42
Net Cash From Continuing Financing Activities
-623 -460 -294 -168 -137 -37 -81 -109 -114 -42
Repayment of Debt
-192 -2.30 -46 -2.20 -2.30 -138 -0.10 -36 -70 -100
Repurchase of Common Equity
-561 -438 -203 -137 -116 -83 -71 -74 -52 0.00
Payment of Dividends
-59 -57 -54 -51 -48 -45 -42 -39 -36 -32
Issuance of Debt
165 0.00 0.00 - - 199 0.00 0.00 - 71
Issuance of Common Equity
7.20 7.10 7.30 7.70 35 33 32 40 30 16
Other Financing Activities, net
18 31 1.50 15 -5.90 -2.20 - - 15 3.50
Effect of Exchange Rate Changes
-21 11 -11 -16 21 -0.70 -5.60 12 -1.30 -22
Cash Interest Paid
0.50 6.00 6.60 8.00 8.10 8.60 8.40 8.00 8.60 15
Cash Income Taxes Paid
71 91 110 172 48 48 42 31 48 33

Quarterly Cash Flow Statements for West Pharmaceutical Services

This table details how cash moves in and out of West Pharmaceutical Services' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-80 -6.30 45 -156 -252 -45 102 -90 -8.00 165 11
Net Cash From Operating Activities
129 190 180 165 118 239 230 169 138 231 169
Net Cash From Continuing Operating Activities
129 190 180 165 118 242 230 169 138 231 169
Net Income / (Loss) Continuing Operations
90 130 136 111 115 137 161 155 140 103 121
Consolidated Net Income / (Loss)
90 130 136 111 115 137 161 155 140 103 121
Depreciation Expense
39 40 39 38 35 35 35 34 31 30 29
Amortization Expense
0.90 0.90 0.90 0.90 0.90 1.30 0.90 0.50 0.90 1.00 0.90
Non-Cash Adjustments To Reconcile Net Income
-0.50 -0.70 4.00 0.70 1.90 42 8.30 5.30 13 12 51
Changes in Operating Assets and Liabilities, net
0.10 20 -0.10 14 -35 27 25 -25 -47 85 -32
Net Cash From Investing Activities
-71 -105 -82 -101 -91 -109 -96 -82 -82 -95 -59
Net Cash From Continuing Investing Activities
-71 -105 -82 -101 -91 -109 -96 -82 -82 -95 -59
Purchase of Property, Plant & Equipment
-71 -105 -81 -100 -91 -109 -96 -75 -82 -95 -58
Net Cash From Financing Activities
-147 -69 -64 -218 -271 -190 -22 -177 -71 -9.50 -75
Net Cash From Continuing Financing Activities
-147 -69 -64 -218 -271 -190 -22 -177 -71 -9.50 -75
Repayment of Debt
-0.20 -23 -110 -58 -0.70 -0.60 -0.60 -0.50 -0.60 -0.50 -43
Repurchase of Common Equity
-134 -54 -52 -187 -267 -177 -28 -173 -60 0.10 -27
Payment of Dividends
-15 -15 -15 -15 -15 -15 -14 -14 -14 -14 -14
Issuance of Common Equity
1.90 1.60 1.90 1.70 2.00 1.80 1.80 1.70 1.80 1.20 2.00
Other Financing Activities, net
0.00 23 -19 5.00 9.40 1.10 18 9.50 2.00 3.80 6.10
Effect of Exchange Rate Changes
8.50 -23 11 -1.10 -8.70 15 -9.80 -0.30 7.00 39 -24

Annual Balance Sheets for West Pharmaceutical Services

This table presents West Pharmaceutical Services' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
3,643 3,830 3,617 3,314 2,794 2,341 1,979 1,863 1,717 1,695
Total Current Assets
1,538 1,936 1,920 1,742 1,374 1,059 894 744 642 674
Cash & Equivalents
485 854 894 763 616 439 337 236 203 275
Accounts Receivable
553 512 507 489 385 319 288 253 201 181
Inventories, net
377 435 415 378 321 236 215 215 199 181
Other Current Assets
124 136 103 112 52 65 54 39 39 37
Plant, Property, & Equipment, net
1,582 1,413 1,158 1,058 943 839 822 855 778 721
Plant, Property & Equipment, gross
2,986 2,738 2,387 2,215 2,036 1,820 1,753 1,746 1,555 1,440
Accumulated Depreciation
1,404 1,325 1,228 1,158 1,092 981 931 891 776 719
Total Noncurrent Assets
524 480 539 514 477 443 263 264 297 300
Long-Term Investments
202 210 205 208 215 193 91 86 83 61
Goodwill
106 109 107 110 111 108 106 108 103 105
Intangible Assets
11 15 18 23 31 30 20 22 23 38
Noncurrent Deferred & Refundable Income Taxes
26 26 66 49 16 14 25 26 66 71
Other Noncurrent Operating Assets
179 121 143 109 92 95 21 23 21 26
Total Liabilities & Shareholders' Equity
3,643 3,830 3,617 3,314 2,794 2,341 1,979 1,863 1,717 1,695
Total Liabilities
961 949 932 978 939 768 583 583 599 671
Total Current Liabilities
550 672 519 594 503 342 284 280 241 314
Short-Term Debt
0.00 134 2.20 44 2.30 2.30 0.10 0.00 2.40 69
Accounts Payable
239 242 215 232 213 157 130 138 122 120
Current Deferred & Payable Income Tax Liabilities
32 17 25 26 26 6.40 9.80 6.00 4.50 13
Current Employee Benefit Liabilities
74 - 77 2.40 2.30 2.20 2.30 58 54 59
Other Current Liabilities
206 173 200 173 154 101 77 77 58 54
Total Noncurrent Liabilities
411 277 413 384 436 427 299 303 358 357
Long-Term Debt
203 73 207 209 253 255 196 197 226 229
Noncurrent Deferred & Payable Income Tax Liabilities
21 13 14 4.90 10 16 13 10 9.20 12
Noncurrent Employee Benefit Liabilities
44 48 47 69 80 70 56 53 76 62
Other Noncurrent Operating Liabilities
144 143 145 101 92 86 34 43 47 54
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
2,682 2,881 2,685 2,335 1,855 1,573 1,396 1,280 1,118 1,024
Total Preferred & Common Equity
2,682 2,881 2,685 2,335 1,855 1,573 1,396 1,280 1,118 1,024
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,682 2,881 2,685 2,335 1,855 1,573 1,396 1,280 1,118 1,024
Common Stock
41 139 251 268 286 292 301 328 279 226
Retained Earnings
3,957 3,523 2,988 2,457 1,847 1,549 1,353 1,178 1,072 965
Treasury Stock
-1,057 -638 -371 -230 -168 -118 -104 -109 -46 -4.00
Accumulated Other Comprehensive Income / (Loss)
-258 -144 -183 -160 -111 -150 -154 -117 -187 -163

Quarterly Balance Sheets for West Pharmaceutical Services

This table presents West Pharmaceutical Services' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
3,618 3,643 3,675 3,489 3,602 3,830 3,755 3,670 3,724 3,617 3,317
Total Current Assets
1,458 1,538 1,551 1,483 1,693 1,936 1,972 1,874 1,937 1,920 1,734
Cash & Equivalents
404 485 491 446 602 854 899 796 886 894 729
Accounts Receivable
544 553 524 479 524 512 519 534 513 507 485
Inventories, net
389 377 401 419 430 435 432 449 447 415 413
Other Current Assets
121 124 134 138 137 136 123 94 91 103 106
Plant, Property, & Equipment, net
1,632 1,582 1,571 1,494 1,449 1,413 1,312 1,261 1,215 1,158 1,069
Plant, Property & Equipment, gross
3,005 2,986 2,991 2,864 2,791 2,738 2,607 2,543 2,479 2,387 2,233
Accumulated Depreciation
1,374 1,404 1,420 1,370 1,343 1,325 1,296 1,282 1,264 1,228 1,164
Total Noncurrent Assets
529 524 554 513 461 480 471 534 571 539 514
Long-Term Investments
212 202 218 198 203 210 195 203 209 205 189
Goodwill
108 106 109 107 108 109 107 108 108 107 104
Intangible Assets
10 11 12 13 14 15 16 17 18 18 18
Noncurrent Deferred & Refundable Income Taxes
26 26 38 34 21 26 17 67 99 66 63
Other Noncurrent Operating Assets
174 179 177 160 116 121 136 140 138 143 139
Total Liabilities & Shareholders' Equity
3,618 3,643 3,675 3,489 3,602 3,830 3,755 3,670 3,724 3,617 3,317
Total Liabilities
935 961 923 913 922 949 887 923 947 932 846
Total Current Liabilities
527 550 517 634 648 672 534 512 535 519 457
Accounts Payable
228 239 224 212 240 242 220 218 234 215 189
Accrued Expenses
68 - - 83 67 106 - 85 - - -
Current Deferred & Payable Income Tax Liabilities
22 32 33 17 17 17 15 27 59 25 30
Other Current Liabilities
208 206 179 189 192 173 153 179 174 200 167
Total Noncurrent Liabilities
408 411 407 279 273 277 353 411 413 413 389
Long-Term Debt
203 203 203 73 73 73 152 206 206 207 207
Noncurrent Deferred & Payable Income Tax Liabilities
21 21 9.40 14 13 13 17 15 15 14 17
Noncurrent Employee Benefit Liabilities
40 44 45 45 48 48 46 48 46 47 54
Other Noncurrent Operating Liabilities
145 144 149 148 140 143 138 142 146 145 111
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
2,683 2,682 2,752 2,577 2,681 2,881 2,868 2,747 2,776 2,685 2,471
Total Preferred & Common Equity
2,683 2,682 2,752 2,577 2,681 2,881 2,868 2,747 2,776 2,685 2,471
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,683 2,682 2,752 2,577 2,681 2,881 2,868 2,747 2,776 2,685 2,471
Common Stock
21 41 42 52 74 139 141 177 200 251 249
Retained Earnings
4,031 3,957 3,857 3,721 3,624 3,523 3,416 3,255 3,114 2,988 2,913
Treasury Stock
-1,163 -1,057 -1,011 -980 -825 -638 -466 -501 - -371 -383
Accumulated Other Comprehensive Income / (Loss)
-206 -258 -136 -217 -192 -144 -223 -184 -168 -183 -309

Annual Metrics And Ratios for West Pharmaceutical Services

This table displays calculated financial ratios and metrics derived from West Pharmaceutical Services' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
-1.92% 2.18% 1.95% 31.89% 16.69% 7.13% 7.40% 5.96% 7.81% -1.52%
EBITDA Growth
-11.27% 1.62% -8.55% 69.84% 29.33% 13.80% 7.92% 13.25% 31.58% -19.67%
EBIT Growth
-16.22% -0.54% -9.71% 85.27% 37.64% 20.04% 7.91% 16.31% 53.03% -29.34%
NOPAT Growth
-16.55% -8.62% -5.34% 93.35% 40.89% 18.93% 38.50% 3.17% 40.00% -24.17%
Net Income Growth
-16.97% 1.28% -11.47% 91.16% 43.24% 16.82% 37.29% 4.94% 50.21% -24.78%
EPS Growth
-15.10% 1.94% -10.84% 89.72% 42.37% 17.15% 37.69% 4.19% 46.92% -25.71%
Operating Cash Flow Growth
-15.85% 7.25% 23.97% 23.60% 28.68% 27.23% 9.61% 20.01% 3.30% 16.13%
Free Cash Flow Firm Growth
-11.36% -24.31% 41.72% 21.15% 25.21% 5.97% 289.60% -24.89% -27.53% -37.52%
Invested Capital Growth
8.61% 12.78% 10.91% 26.46% 6.74% 3.00% 0.74% 8.94% 7.52% 0.99%
Revenue Q/Q Growth
0.58% 0.80% -0.76% 5.62% 5.38% 2.68% 0.40% 2.13% 1.52% 0.71%
EBITDA Q/Q Growth
0.35% 5.02% -11.94% 9.08% 8.61% 2.78% 2.27% 4.13% 3.08% 0.88%
EBIT Q/Q Growth
-0.40% 5.30% -13.40% 9.75% 10.51% 3.78% 2.66% 4.95% 4.85% 0.47%
NOPAT Q/Q Growth
-0.83% 5.09% -7.45% 9.13% 11.39% 4.68% 35.97% -21.33% 2.50% 1.30%
Net Income Q/Q Growth
-1.38% 6.08% -7.09% 8.05% 11.07% 5.18% 33.57% -20.64% 4.21% 2.14%
EPS Q/Q Growth
-0.74% 6.20% -6.42% 7.70% 10.39% 5.59% 33.01% -20.40% 3.24% 0.00%
Operating Cash Flow Q/Q Growth
-6.98% 1.08% 10.70% 2.12% 9.83% 9.94% -2.80% 3.82% 1.76% 11.55%
Free Cash Flow Firm Q/Q Growth
42.39% 5.34% -3.49% 7.91% 3.95% 2.42% 6.39% -35.71% 106.83% -25.56%
Invested Capital Q/Q Growth
-2.14% 2.14% 1.82% 4.21% 2.72% 0.79% 0.31% -3.15% -2.38% 0.45%
Profitability Metrics
- - - - - - - - - -
Gross Margin
34.51% 38.28% 39.36% 41.52% 35.76% 32.92% 31.76% 32.07% 33.23% 32.56%
EBITDA Margin
25.03% 27.67% 27.83% 31.02% 24.09% 21.73% 20.46% 20.36% 19.05% 15.61%
Operating Margin
19.70% 22.92% 25.43% 26.57% 18.95% 16.12% 13.99% 14.12% 12.93% 9.19%
EBIT Margin
19.66% 23.02% 23.65% 26.70% 19.01% 16.12% 14.38% 14.31% 13.04% 9.19%
Profit (Net Income) Margin
17.03% 20.12% 20.30% 23.37% 16.13% 13.14% 12.05% 9.42% 9.52% 6.83%
Tax Burden Percent
84.15% 85.01% 86.17% 88.37% 86.27% 82.83% 85.96% 67.76% 75.66% 82.34%
Interest Burden Percent
102.92% 102.80% 99.59% 99.05% 98.33% 98.41% 97.45% 97.16% 96.44% 90.28%
Effective Tax Rate
18.36% 17.52% 16.87% 14.31% 18.07% 20.22% 17.20% 36.38% 28.66% 22.65%
Return on Invested Capital (ROIC)
22.04% 29.20% 35.76% 44.49% 26.91% 20.03% 17.16% 12.97% 13.61% 10.14%
ROIC Less NNEP Spread (ROIC-NNEP)
17.95% 25.10% 38.78% 41.83% 24.21% 18.36% 12.72% 5.23% 4.44% 52.88%
Return on Net Nonoperating Assets (RNNOA)
-4.33% -7.88% -12.42% -12.90% -6.71% -3.75% -1.70% -0.40% -0.20% -0.48%
Return on Equity (ROE)
17.71% 21.32% 23.34% 31.59% 20.20% 16.28% 15.46% 12.57% 13.41% 9.65%
Cash Return on Invested Capital (CROIC)
13.78% 17.19% 25.42% 21.12% 20.38% 17.08% 16.42% 4.41% 6.36% 9.15%
Operating Return on Assets (OROA)
15.23% 18.24% 19.70% 24.76% 15.89% 13.73% 12.86% 12.79% 11.54% 7.64%
Return on Assets (ROA)
13.19% 15.94% 16.91% 21.67% 13.48% 11.19% 10.77% 8.42% 8.42% 5.68%
Return on Common Equity (ROCE)
17.71% 21.32% 23.34% 31.59% 20.20% 16.28% 15.46% 12.57% 13.41% 9.65%
Return on Equity Simple (ROE_SIMPLE)
18.37% 20.60% 21.82% 28.34% 18.67% 15.36% 14.82% 11.77% 12.85% 9.34%
Net Operating Profit after Tax (NOPAT)
465 558 610 645 333 237 199 144 139 99
NOPAT Margin
16.08% 18.90% 21.14% 22.77% 15.53% 12.86% 11.59% 8.98% 9.23% 7.11%
Net Nonoperating Expense Percent (NNEP)
4.09% 4.10% -3.02% 2.66% 2.70% 1.67% 4.44% 7.74% 9.17% -42.74%
Return On Investment Capital (ROIC_SIMPLE)
16.13% 18.06% 21.09% - - - - - - -
Cost of Revenue to Revenue
65.49% 61.72% 60.64% 58.48% 64.24% 67.08% 68.24% 67.93% 66.77% 67.44%
SG&A Expenses to Revenue
11.70% 11.98% 10.98% 12.81% 14.07% 14.82% 15.31% 15.38% 15.88% 16.65%
R&D to Revenue
2.39% 2.32% 2.03% 1.86% 2.18% 2.11% 2.35% 2.45% 2.44% 2.44%
Operating Expenses to Revenue
14.81% 15.36% 13.93% 14.96% 16.81% 16.80% 17.77% 17.95% 20.29% 23.37%
Earnings before Interest and Taxes (EBIT)
569 679 683 756 408 297 247 229 197 129
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
724 816 803 878 517 400 351 326 288 219
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
8.84 9.02 6.46 14.79 11.21 6.99 5.12 5.60 5.40 4.09
Price to Tangible Book Value (P/TBV)
9.24 9.42 6.78 15.68 12.13 7.66 5.63 6.23 6.09 4.75
Price to Revenue (P/Rev)
8.19 8.81 6.01 12.20 9.68 5.98 4.16 4.48 4.00 2.99
Price to Earnings (P/E)
48.12 43.77 29.60 52.19 60.02 45.52 34.54 47.57 42.05 43.85
Dividend Yield
0.25% 0.22% 0.31% 0.15% 0.23% 0.41% 0.59% 0.55% 0.59% 0.77%
Earnings Yield
2.08% 2.28% 3.38% 1.92% 1.67% 2.20% 2.90% 2.10% 2.38% 2.28%
Enterprise Value to Invested Capital (EV/IC)
10.56 12.41 9.17 20.90 15.79 8.87 5.94 6.10 5.64 4.21
Enterprise Value to Revenue (EV/Rev)
8.03 8.52 5.70 11.94 9.41 5.78 4.03 4.40 3.96 2.97
Enterprise Value to EBITDA (EV/EBITDA)
32.06 30.77 20.48 38.50 39.07 26.57 19.67 21.63 20.80 19.01
Enterprise Value to EBIT (EV/EBIT)
40.82 36.99 24.10 44.73 49.51 35.84 27.99 30.77 30.39 32.30
Enterprise Value to NOPAT (EV/NOPAT)
49.91 45.05 26.96 52.47 60.60 44.91 34.75 49.03 42.95 41.76
Enterprise Value to Operating Cash Flow (EV/OCF)
35.54 32.35 22.72 57.92 42.76 28.94 23.96 26.75 27.26 19.56
Enterprise Value to Free Cash Flow (EV/FCFF)
79.82 76.52 37.93 110.53 79.99 52.68 36.32 144.15 91.94 46.28
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.08 0.07 0.08 0.11 0.14 0.16 0.14 0.15 0.20 0.29
Long-Term Debt to Equity
0.08 0.03 0.08 0.09 0.14 0.16 0.14 0.15 0.20 0.22
Financial Leverage
-0.24 -0.31 -0.32 -0.31 -0.28 -0.20 -0.13 -0.08 -0.04 -0.01
Leverage Ratio
1.34 1.34 1.38 1.46 1.50 1.45 1.44 1.49 1.59 1.70
Compound Leverage Factor
1.38 1.38 1.37 1.44 1.47 1.43 1.40 1.45 1.54 1.53
Debt to Total Capital
7.02% 6.70% 7.22% 9.77% 12.10% 14.06% 12.31% 13.34% 16.98% 22.56%
Short-Term Debt to Total Capital
0.00% 4.34% 0.08% 1.71% 0.11% 0.13% 0.01% 0.00% 0.18% 5.24%
Long-Term Debt to Total Capital
7.02% 2.36% 7.14% 8.07% 11.99% 13.93% 12.31% 13.34% 16.80% 17.31%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
92.98% 93.30% 92.78% 90.23% 87.90% 85.94% 87.69% 86.66% 83.02% 77.45%
Debt to EBITDA
0.28 0.25 0.26 0.29 0.49 0.64 0.56 0.61 0.80 1.36
Net Debt to EBITDA
-0.67 -1.05 -1.11 -0.82 -1.11 -0.94 -0.66 -0.38 -0.20 -0.17
Long-Term Debt to EBITDA
0.28 0.09 0.26 0.24 0.49 0.64 0.56 0.61 0.79 1.05
Debt to NOPAT
0.44 0.37 0.34 0.39 0.77 1.09 0.99 1.37 1.64 3.00
Net Debt to NOPAT
-1.04 -1.54 -1.46 -1.11 -1.72 -1.58 -1.17 -0.87 -0.41 -0.38
Long-Term Debt to NOPAT
0.44 0.13 0.34 0.32 0.76 1.08 0.99 1.37 1.62 2.30
Altman Z-Score
17.96 19.47 14.21 24.24 15.82 11.09 9.97 9.83 8.46 5.87
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.79 2.88 3.70 2.93 2.73 3.10 3.15 2.66 2.66 2.14
Quick Ratio
1.88 2.03 2.70 2.11 1.99 2.22 2.21 1.75 1.67 1.45
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
291 328 434 306 253 202 190 49 65 90
Operating Cash Flow to CapEx
173.32% 214.50% 254.39% 230.47% 270.93% 290.51% 275.64% 201.30% 128.91% 161.40%
Free Cash Flow to Firm to Interest Expense
96.99 36.47 54.90 37.32 30.80 23.73 22.66 6.26 8.03 6.37
Operating Cash Flow to Interest Expense
217.80 86.28 91.65 71.22 57.62 43.20 34.36 33.76 27.09 15.06
Operating Cash Flow Less CapEx to Interest Expense
92.13 46.06 55.62 40.32 36.35 28.33 21.89 16.99 6.07 5.73
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.77 0.79 0.83 0.93 0.84 0.85 0.89 0.89 0.88 0.83
Accounts Receivable Turnover
5.44 5.79 5.79 6.48 6.09 6.06 6.34 7.05 7.90 7.77
Inventory Turnover
4.67 4.29 4.41 4.73 4.95 5.48 5.46 5.24 5.30 5.21
Fixed Asset Turnover
1.93 2.29 2.61 2.83 2.41 2.22 2.05 1.96 2.01 1.96
Accounts Payable Turnover
7.87 7.95 7.82 7.44 7.46 8.59 8.73 8.35 8.34 8.47
Days Sales Outstanding (DSO)
67.15 63.07 62.99 56.35 59.90 60.26 57.53 51.78 46.18 46.99
Days Inventory Outstanding (DIO)
78.18 85.16 82.69 77.12 73.71 66.57 66.91 69.64 68.89 70.10
Days Payable Outstanding (DPO)
46.40 45.89 46.66 49.08 48.95 42.47 41.81 43.70 43.79 43.09
Cash Conversion Cycle (CCC)
98.93 102.33 99.02 84.39 84.65 84.36 82.63 77.72 71.29 74.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
2,198 2,024 1,795 1,618 1,280 1,199 1,164 1,155 1,060 986
Invested Capital Turnover
1.37 1.55 1.69 1.95 1.73 1.56 1.48 1.44 1.47 1.43
Increase / (Decrease) in Invested Capital
174 229 177 339 81 35 8.60 95 74 9.70
Enterprise Value (EV)
23,223 25,118 16,451 33,823 20,205 10,627 6,914 7,044 5,981 4,154
Market Capitalization
23,708 25,975 17,341 34,540 20,780 11,001 7,146 7,168 6,038 4,192
Book Value per Share
$37.04 $38.94 $36.27 $31.53 $25.09 $21.26 $18.85 $17.24 $15.27 $14.20
Tangible Book Value per Share
$35.42 $37.27 $34.57 $29.73 $23.17 $19.40 $17.15 $15.49 $13.54 $12.23
Total Capital
2,885 3,088 2,894 2,588 2,110 1,831 1,592 1,477 1,346 1,322
Total Debt
203 207 209 253 255 257 196 197 229 298
Total Long-Term Debt
203 73 207 209 253 255 196 197 226 229
Net Debt
-484 -857 -890 -717 -575 -375 -233 -125 -57 -38
Capital Expenditures (CapEx)
377 362 285 253 174 126 105 131 170 132
Debt-free, Cash-free Net Working Capital (DFCFNWC)
503 545 508 430 257 280 273 228 200 154
Debt-free Net Working Capital (DFNWC)
988 1,399 1,403 1,192 873 719 611 464 403 429
Net Working Capital (NWC)
988 1,265 1,401 1,148 870 717 611 464 401 359
Net Nonoperating Expense (NNE)
-27 -36 24 -17 -13 -5.07 -7.93 -7.04 -4.35 3.87
Net Nonoperating Obligations (NNO)
-484 -857 -890 -717 -575 -375 -233 -125 -57 -38
Total Depreciation and Amortization (D&A)
155 137 121 122 109 103 104 97 91 90
Debt-free, Cash-free Net Working Capital to Revenue
17.39% 18.47% 17.61% 15.17% 11.98% 15.23% 15.92% 14.26% 13.27% 11.01%
Debt-free Net Working Capital to Revenue
34.14% 47.41% 48.59% 42.10% 40.64% 39.10% 35.57% 29.02% 26.72% 30.63%
Net Working Capital to Revenue
34.14% 42.87% 48.51% 40.54% 40.54% 38.97% 35.56% 29.02% 26.57% 25.68%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$6.75 $7.98 $7.87 $8.89 $4.68 $3.27 $2.80 $2.04 $1.96 $1.33
Adjusted Weighted Average Basic Shares Outstanding
73M 74.30M 74.40M 74.40M 73.90M 74M 73.90M 73.90M 73.30M 72M
Adjusted Diluted Earnings per Share
$6.69 $7.88 $7.73 $8.67 $4.57 $3.21 $2.74 $1.99 $1.91 $1.30
Adjusted Weighted Average Diluted Shares Outstanding
73.70M 75.30M 75.80M 76.30M 75.80M 75.40M 75.40M 75.80M 75M 73.80M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
72.30M 73.30M 74.14M 74.28M 74.10M 147.67M 74.19M 73.99M 73.26M 72.33M
Normalized Net Operating Profit after Tax (NOPAT)
465 558 610 645 333 237 199 144 139 99
Normalized NOPAT Margin
16.08% 18.90% 21.14% 22.77% 15.53% 12.86% 11.59% 8.98% 9.23% 7.11%
Pre Tax Income Margin
20.24% 23.66% 23.55% 26.45% 18.69% 15.86% 14.02% 13.91% 12.58% 8.29%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
189.63 75.44 86.42 92.21 49.77 34.88 29.40 29.35 24.30 9.12
NOPAT to Interest Expense
155.09 61.95 77.24 78.61 40.66 27.84 23.69 18.42 17.19 7.05
EBIT Less CapEx to Interest Expense
63.97 35.22 50.39 61.30 28.50 20.01 16.94 12.58 3.28 -0.21
NOPAT Less CapEx to Interest Expense
29.42 21.73 41.21 47.71 19.39 12.97 11.22 1.65 -3.82 -2.28
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
12.00% 9.61% 9.23% 7.72% 13.89% 18.66% 20.35% 25.95% 24.93% 33.89%
Augmented Payout Ratio
125.84% 83.47% 43.85% 28.44% 47.26% 53.04% 54.57% 75.32% 61.28% 33.89%

Quarterly Metrics And Ratios for West Pharmaceutical Services

This table displays calculated financial ratios and metrics derived from West Pharmaceutical Services' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.37% 2.30% -0.07% -6.86% -2.96% 3.29% 8.81% -2.27% -0.47% -3.02% -2.77%
EBITDA Growth
-7.32% 1.78% -7.38% -23.81% -15.25% 22.39% 30.05% -16.24% -14.77% -26.44% -21.55%
EBIT Growth
-13.03% -0.81% -11.32% -30.89% -20.93% 24.06% 32.29% -20.12% -18.13% -29.59% -24.99%
NOPAT Growth
-21.80% -3.06% -13.31% -29.31% -19.00% 27.17% -5.61% -19.47% -21.51% -32.68% -6.54%
Net Income Growth
-22.12% -5.04% -15.69% -28.24% -17.64% 33.01% 33.75% -17.72% -19.45% -30.26% -31.32%
EPS Growth
-20.65% -2.73% -13.55% -26.70% -16.22% 33.58% 34.59% -16.94% -19.21% -27.89% -31.17%
Operating Cash Flow Growth
9.48% -20.49% -21.73% -2.48% -14.41% 3.60% 36.23% -2.25% -8.66% 43.53% -11.15%
Free Cash Flow Firm Growth
-20.12% 50.38% -94.70% -83.07% -58.25% -33.56% -34.67% 47.88% 62.89% 59.87% 62.54%
Invested Capital Growth
8.98% 8.61% 13.36% 9.35% 10.22% 12.78% 12.42% 10.81% 10.95% 10.91% 13.52%
Revenue Q/Q Growth
-6.78% 0.25% 6.38% 0.96% -5.00% -2.06% -0.85% 5.19% 1.11% 3.17% -10.94%
EBITDA Q/Q Growth
-26.71% -0.25% 21.62% 4.23% -19.51% -9.23% 0.05% 15.94% 16.23% -3.54% -35.56%
EBIT Q/Q Growth
-33.08% -0.62% 27.26% 2.77% -23.68% -11.15% -0.82% 17.58% 19.74% -5.26% -40.11%
NOPAT Q/Q Growth
-32.52% -4.28% 23.69% -2.12% -16.35% -14.41% 0.86% 12.16% 31.33% -36.47% -13.95%
Net Income Q/Q Growth
-30.98% -4.34% 22.19% -3.47% -15.84% -15.07% 4.00% 10.79% 35.92% -14.59% -36.02%
EPS Q/Q Growth
-30.90% -3.78% 22.52% -2.58% -15.30% -14.49% 3.88% 11.35% 35.04% -13.84% -35.89%
Operating Cash Flow Q/Q Growth
-31.93% 5.55% 9.15% 39.59% -50.56% 3.91% 35.99% 22.52% -40.16% 36.65% -2.43%
Free Cash Flow Firm Q/Q Growth
-105.57% 62.80% -73.26% 9.33% 15.08% -45.96% -62.90% 21.62% 28.33% -47.17% 36.96%
Invested Capital Q/Q Growth
3.25% -2.14% 5.06% 2.67% 2.90% 2.14% 1.33% 3.49% 5.28% 1.82% -0.11%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
33.22% 36.54% 35.44% 32.76% 33.10% 38.01% 38.57% 38.66% 37.86% 36.98% 39.02%
EBITDA Margin
21.03% 26.75% 26.88% 23.52% 22.78% 26.89% 29.01% 28.75% 26.08% 22.69% 24.27%
Operating Margin
15.33% 21.31% 21.60% 17.97% 17.66% 21.98% 23.72% 24.21% 21.67% 18.30% 27.11%
EBIT Margin
15.30% 21.31% 21.50% 17.97% 17.66% 21.98% 24.23% 24.22% 21.67% 18.30% 19.93%
Profit (Net Income) Margin
12.87% 17.37% 18.21% 15.85% 16.58% 18.72% 21.58% 20.58% 19.54% 14.53% 17.56%
Tax Burden Percent
81.27% 78.90% 82.67% 86.48% 90.50% 81.45% 86.26% 83.88% 88.66% 80.03% 88.55%
Interest Burden Percent
103.46% 103.32% 102.43% 101.98% 103.75% 104.54% 103.26% 101.26% 101.67% 99.23% 99.49%
Effective Tax Rate
21.81% 22.32% 19.70% 17.02% 12.87% 20.51% 15.72% 18.82% 14.95% 22.46% 14.98%
Return on Invested Capital (ROIC)
15.95% 22.69% 23.60% 20.97% 22.69% 26.99% 31.25% 30.28% 29.59% 24.01% 40.45%
ROIC Less NNEP Spread (ROIC-NNEP)
14.74% 21.78% 22.67% 19.90% 21.57% 25.95% 29.76% 29.33% 28.54% 23.71% 46.00%
Return on Net Nonoperating Assets (RNNOA)
-2.78% -5.25% -5.62% -4.60% -5.87% -8.15% -8.89% -8.23% -8.45% -7.59% -13.37%
Return on Equity (ROE)
13.17% 17.44% 17.98% 16.37% 16.82% 18.85% 22.36% 22.05% 21.14% 16.42% 27.08%
Cash Return on Invested Capital (CROIC)
11.71% 13.78% 9.67% 14.96% 17.09% 17.19% 16.65% 18.66% 21.55% 25.42% 27.11%
Operating Return on Assets (OROA)
12.27% 16.50% 16.65% 14.45% 14.12% 17.42% 20.06% 19.75% 17.81% 15.25% 17.95%
Return on Assets (ROA)
10.32% 13.45% 14.10% 12.74% 13.26% 14.83% 17.86% 16.77% 16.05% 12.11% 15.81%
Return on Common Equity (ROCE)
13.17% 17.44% 17.98% 16.37% 16.82% 18.85% 22.36% 22.05% 21.14% 16.42% 27.08%
Return on Equity Simple (ROE_SIMPLE)
17.41% 0.00% 18.15% 20.37% 21.22% 0.00% 19.50% 18.88% 19.89% 0.00% 25.52%
Net Operating Profit after Tax (NOPAT)
84 124 130 105 107 128 149 148 132 101 158
NOPAT Margin
11.99% 16.56% 17.34% 14.92% 15.39% 17.47% 19.99% 19.65% 18.43% 14.19% 23.05%
Net Nonoperating Expense Percent (NNEP)
1.21% 0.91% 0.93% 1.07% 1.12% 1.04% 1.49% 0.96% 1.05% 0.30% -5.55%
Return On Investment Capital (ROIC_SIMPLE)
2.90% 4.30% - - - 4.14% - - - 3.48% -
Cost of Revenue to Revenue
66.78% 63.46% 64.56% 67.24% 66.90% 61.99% 61.43% 61.34% 62.14% 63.02% 60.98%
SG&A Expenses to Revenue
12.61% 11.39% 11.18% 11.82% 12.47% 12.30% 11.91% 11.73% 12.00% 12.09% 9.65%
R&D to Revenue
2.34% 2.47% 2.08% 2.49% 2.53% 2.51% 2.19% 2.19% 2.39% 2.24% 1.98%
Operating Expenses to Revenue
17.89% 15.22% 13.84% 14.78% 15.44% 16.02% 14.85% 14.45% 16.19% 18.68% 11.91%
Earnings before Interest and Taxes (EBIT)
107 160 161 126 123 161 181 183 155 130 137
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
147 200 201 165 158 197 217 217 187 161 167
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
6.03 8.84 7.91 9.31 10.91 9.02 9.65 10.31 9.23 6.46 7.34
Price to Tangible Book Value (P/TBV)
6.31 9.24 8.28 9.76 11.43 9.42 10.08 10.81 9.66 6.78 7.72
Price to Revenue (P/Rev)
5.59 8.19 7.57 8.33 9.99 8.81 9.45 9.89 8.88 6.01 6.24
Price to Earnings (P/E)
34.65 48.12 43.58 45.68 51.42 43.77 49.46 54.62 46.40 29.60 28.77
Dividend Yield
0.37% 0.25% 0.20% 0.18% 0.15% 0.22% 0.20% 0.20% 0.21% 0.31% 0.29%
Earnings Yield
2.89% 2.08% 2.29% 2.19% 1.94% 2.28% 2.02% 1.83% 2.16% 3.38% 3.48%
Enterprise Value to Invested Capital (EV/IC)
6.95 10.56 9.47 11.01 13.76 12.41 13.51 14.08 13.09 9.17 9.89
Enterprise Value to Revenue (EV/Rev)
5.45 8.03 7.39 8.18 9.78 8.52 9.15 9.61 8.58 5.70 5.99
Enterprise Value to EBITDA (EV/EBITDA)
22.13 32.06 29.47 32.10 36.50 30.77 34.45 35.29 30.08 20.48 19.11
Enterprise Value to EBIT (EV/EBIT)
28.53 40.82 37.23 40.09 44.51 36.99 41.53 42.13 35.35 24.10 22.12
Enterprise Value to NOPAT (EV/NOPAT)
35.70 49.91 45.33 48.13 53.79 45.05 50.48 51.21 43.11 26.96 26.45
Enterprise Value to Operating Cash Flow (EV/OCF)
23.73 35.54 30.28 31.29 37.86 32.35 34.86 38.95 34.78 22.72 26.66
Enterprise Value to Free Cash Flow (EV/FCFF)
61.92 79.82 104.08 76.87 84.39 76.52 85.93 79.36 63.89 37.93 38.80
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.08 0.08 0.07 0.08 0.08 0.07 0.07 0.08 0.08 0.08 0.08
Long-Term Debt to Equity
0.08 0.08 0.07 0.03 0.03 0.03 0.05 0.07 0.07 0.08 0.08
Financial Leverage
-0.19 -0.24 -0.25 -0.23 -0.27 -0.31 -0.30 -0.28 -0.30 -0.32 -0.29
Leverage Ratio
1.35 1.34 1.32 1.34 1.34 1.34 1.32 1.36 1.38 1.38 1.38
Compound Leverage Factor
1.39 1.39 1.35 1.37 1.39 1.40 1.37 1.38 1.40 1.37 1.38
Debt to Total Capital
7.02% 7.02% 6.86% 7.40% 7.14% 6.70% 6.74% 7.03% 6.98% 7.22% 7.81%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 4.78% 4.62% 4.34% 1.79% 0.07% 0.07% 0.08% 0.08%
Long-Term Debt to Total Capital
7.02% 7.02% 6.86% 2.62% 2.52% 2.36% 4.95% 6.96% 6.91% 7.14% 7.73%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
92.98% 92.98% 93.14% 92.60% 92.86% 93.30% 93.26% 92.97% 93.02% 92.78% 92.19%
Debt to EBITDA
0.28 0.28 0.28 0.28 0.26 0.25 0.27 0.27 0.25 0.26 0.23
Net Debt to EBITDA
-0.58 -0.67 -0.70 -0.60 -0.76 -1.05 -1.14 -1.01 -1.08 -1.11 -0.78
Long-Term Debt to EBITDA
0.28 0.28 0.28 0.10 0.09 0.09 0.20 0.26 0.25 0.26 0.23
Debt to NOPAT
0.46 0.44 0.43 0.42 0.39 0.37 0.39 0.39 0.36 0.34 0.32
Net Debt to NOPAT
-0.94 -1.04 -1.08 -0.90 -1.12 -1.54 -1.67 -1.47 -1.55 -1.46 -1.07
Long-Term Debt to NOPAT
0.46 0.44 0.43 0.15 0.14 0.13 0.29 0.38 0.36 0.34 0.31
Altman Z-Score
13.15 17.58 16.89 18.49 21.72 19.02 21.40 21.05 18.76 13.70 15.57
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.77 2.79 3.00 2.34 2.61 2.88 3.70 3.66 3.62 3.70 3.80
Quick Ratio
1.80 1.88 1.97 1.46 1.74 2.03 2.66 2.60 2.62 2.70 2.66
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-103 -50 -135 -78 -86 -101 -69 -43 -54 -76 -52
Operating Cash Flow to CapEx
181.49% 181.22% 221.53% 164.67% 130.46% 219.96% 240.19% 224.40% 168.21% 243.20% 292.21%
Free Cash Flow to Firm to Interest Expense
-258.59 0.00 -193.24 -52.05 -53.82 -84.50 -23.96 -15.80 -24.73 -44.66 -23.45
Operating Cash Flow to Interest Expense
323.50 0.00 257.29 110.00 73.88 199.25 79.34 62.67 62.77 135.76 76.77
Operating Cash Flow Less CapEx to Interest Expense
145.25 0.00 141.14 43.20 17.25 108.67 46.31 34.74 25.45 79.94 50.50
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.80 0.77 0.77 0.80 0.80 0.79 0.83 0.82 0.82 0.83 0.90
Accounts Receivable Turnover
5.42 5.44 5.51 5.68 5.65 5.79 5.83 5.39 5.70 5.79 6.05
Inventory Turnover
4.63 4.67 4.50 4.26 4.20 4.29 4.29 4.12 4.08 4.41 4.52
Fixed Asset Turnover
1.88 1.93 2.00 2.09 2.20 2.29 2.46 2.45 2.53 2.61 2.80
Accounts Payable Turnover
8.09 7.87 8.44 8.61 7.77 7.95 8.87 8.10 7.31 7.82 8.75
Days Sales Outstanding (DSO)
67.28 67.15 66.20 64.31 64.65 63.07 62.64 67.68 64.06 62.99 60.33
Days Inventory Outstanding (DIO)
78.81 78.18 81.15 85.68 86.95 85.16 85.03 88.62 89.51 82.69 80.70
Days Payable Outstanding (DPO)
45.11 46.40 43.27 42.38 46.99 45.89 41.13 45.08 49.96 46.66 41.73
Cash Conversion Cycle (CCC)
100.99 98.93 104.09 107.60 104.61 102.33 106.53 111.21 103.60 99.02 99.30
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
2,270 2,198 2,246 2,138 2,083 2,024 1,982 1,955 1,889 1,795 1,763
Invested Capital Turnover
1.33 1.37 1.36 1.41 1.47 1.55 1.56 1.54 1.61 1.69 1.75
Increase / (Decrease) in Invested Capital
187 174 265 183 193 229 219 191 187 177 210
Enterprise Value (EV)
15,774 23,223 21,268 23,539 28,645 25,118 26,779 27,541 24,728 16,451 17,435
Market Capitalization
16,187 23,708 21,774 23,978 29,243 25,975 27,665 28,332 25,615 17,341 18,143
Book Value per Share
$37.11 $37.04 $37.94 $35.37 $36.47 $38.94 $38.83 $37.00 $37.45 $36.27 $33.37
Tangible Book Value per Share
$35.48 $35.42 $36.27 $33.72 $34.82 $37.27 $37.17 $35.32 $35.75 $34.57 $31.72
Total Capital
2,886 2,885 2,955 2,783 2,887 3,088 3,076 2,955 2,985 2,894 2,680
Total Debt
203 203 203 206 206 207 207 208 208 209 209
Total Long-Term Debt
203 203 203 73 73 73 152 206 206 207 207
Net Debt
-414 -484 -506 -439 -598 -857 -887 -791 -887 -890 -708
Capital Expenditures (CapEx)
71 105 81 100 91 109 96 75 82 95 58
Debt-free, Cash-free Net Working Capital (DFCFNWC)
527 503 543 536 576 545 595 569 518 508 550
Debt-free Net Working Capital (DFNWC)
931 988 1,034 982 1,178 1,399 1,494 1,365 1,405 1,403 1,279
Net Working Capital (NWC)
931 988 1,034 849 1,045 1,265 1,439 1,363 1,402 1,401 1,277
Net Nonoperating Expense (NNE)
-6.14 -6.12 -6.47 -6.57 -8.31 -9.10 -12 -6.95 -7.91 -2.42 38
Net Nonoperating Obligations (NNO)
-414 -484 -506 -439 -598 -857 -887 -791 -887 -890 -708
Total Depreciation and Amortization (D&A)
40 41 40 39 36 36 36 34 32 31 30
Debt-free, Cash-free Net Working Capital to Revenue
18.19% 17.39% 18.88% 18.63% 19.67% 18.47% 20.35% 19.84% 17.97% 17.61% 18.91%
Debt-free Net Working Capital to Revenue
32.14% 34.14% 35.95% 34.14% 40.22% 47.41% 51.05% 47.62% 48.71% 48.59% 43.97%
Net Working Capital to Revenue
32.14% 34.14% 35.95% 29.52% 35.67% 42.87% 49.16% 47.54% 48.63% 48.51% 43.89%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.24 $1.79 $1.87 $1.52 $1.57 $1.85 $2.17 $2.08 $1.88 $1.38 $1.62
Adjusted Weighted Average Basic Shares Outstanding
72.50M 73M 72.80M 73M 73.50M 74.30M 74.30M 74.30M 74.50M 74.40M 74.40M
Adjusted Diluted Earnings per Share
$1.23 $1.78 $1.85 $1.51 $1.55 $1.83 $2.14 $2.06 $1.85 $1.37 $1.59
Adjusted Weighted Average Diluted Shares Outstanding
73M 73.70M 73.40M 73.70M 74.30M 75.30M 75.30M 75.40M 75.70M 75.80M 75.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
71.85M 72.30M 72.42M 72.54M 72.84M 73.30M 73.99M 73.86M 74.24M 74.14M 74.03M
Normalized Net Operating Profit after Tax (NOPAT)
84 124 130 105 107 128 149 148 132 101 158
Normalized NOPAT Margin
11.99% 16.56% 17.34% 14.92% 15.39% 17.47% 19.99% 19.65% 18.43% 14.19% 23.05%
Pre Tax Income Margin
15.83% 22.02% 22.02% 18.33% 18.32% 22.98% 25.02% 24.53% 22.03% 18.16% 19.83%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
267.00 0.00 229.43 84.13 76.75 134.08 62.45 67.63 70.59 76.29 62.23
NOPAT to Interest Expense
209.16 0.00 185.04 69.82 66.87 106.58 51.53 54.87 60.04 59.16 71.96
EBIT Less CapEx to Interest Expense
88.75 0.00 113.29 17.33 20.13 43.50 29.41 39.70 33.27 20.47 35.95
NOPAT Less CapEx to Interest Expense
30.91 0.00 68.90 3.02 10.25 16.00 18.49 26.95 22.72 3.34 45.69
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
12.76% 12.00% 11.73% 11.07% 10.13% 9.61% 10.06% 10.76% 9.93% 9.23% 8.45%
Augmented Payout Ratio
104.24% 125.84% 148.54% 136.60% 123.58% 83.47% 56.76% 61.00% 30.90% 43.85% 40.63%

Frequently Asked Questions About West Pharmaceutical Services' Financials

When does West Pharmaceutical Services's fiscal year end?

According to the most recent income statement we have on file, West Pharmaceutical Services' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has West Pharmaceutical Services' net income changed over the last 9 years?

West Pharmaceutical Services' net income appears to be on an upward trend, with a most recent value of $492.70 million in 2024, rising from $95.60 million in 2015. The previous period was $593.40 million in 2023. See West Pharmaceutical Services' forecast for analyst expectations on what’s next for the company.

What is West Pharmaceutical Services's operating income?
West Pharmaceutical Services's total operating income in 2024 was $569.90 million, based on the following breakdown:
  • Total Gross Profit: $998.50 million
  • Total Operating Expenses: $428.60 million
How has West Pharmaceutical Services revenue changed over the last 9 years?

Over the last 9 years, West Pharmaceutical Services' total revenue changed from $1.40 billion in 2015 to $2.89 billion in 2024, a change of 106.7%.

How much debt does West Pharmaceutical Services have?

West Pharmaceutical Services' total liabilities were at $961.10 million at the end of 2024, a 1.3% increase from 2023, and a 43.2% increase since 2015.

How much cash does West Pharmaceutical Services have?

In the past 9 years, West Pharmaceutical Services' cash and equivalents has ranged from $203 million in 2016 to $894.30 million in 2022, and is currently $484.60 million as of their latest financial filing in 2024.

How has West Pharmaceutical Services' book value per share changed over the last 9 years?

Over the last 9 years, West Pharmaceutical Services' book value per share changed from 14.20 in 2015 to 37.04 in 2024, a change of 160.8%.



This page (NYSE:WST) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners